#United States #Washington D.C. #cancer detection #Cizzle Bio #Prevent Cancer

Cizzle Bio Champions Early Cancer Detection at Gala

Cizzle Bio Inc., a pioneering biotechnology firm, took center stage at the Prevent Cancer Foundation's 32nd Annual Gala, which took place on September 16, 2026, in Washington, D.C. The event gathered over 800 leaders from cancer research, advocacy, healthcare, and philanthropy, all united with a single mission: to advance strategies for cancer prevention and early detection.

Bill Behnke, the company's Founder and CEO, not only sponsored the gala but also contributed his expertise as a member of the Gala Committee. His personal connection to the cause—his daughter’s battle with lymphoma at the age of three—has fueled his resolve to improve care for patients and their families. "Scientific innovation matters most when it improves patients' lives," Behnke expressed, highlighting Cizzle Bio's core values.

The Prevent Cancer Foundation, recognized for its dedication to cancer awareness and education, saw this gala as an opportunity to shine a light on significant advancements in cancer detection. With a theme celebrating Puerto Rico's strides in this area, the event featured co-chairs like Gov. Jenniffer González-Colón and Rep. Pablo José Hernández Rivera.

The evening's festivities included the presentation of Cancer Champion Awards, honoring notable figures such as House Majority Leader Steve Scalise and Rep. Richard Neal for their efforts to enhance accessibility to cancer preventative services. The gathering raised over $2 million, funds that are earmarked for vital research, including for cancers currently lacking routine screening methods—an initiative that closely aligns with Cizzle Bio's mission.

During the gala, participants witnessed heartfelt tributes including a poignant moment where Dave Mitrani honored his late wife, whose connections to the Prevent Cancer Foundation underscored the real human impact underlying these missions. CNN's Sara Sidner, a breast cancer survivor, served as the master of ceremonies, further emphasizing the importance of community and collaboration in fighting cancer.

Cizzle Bio's flagship innovation, the CIZ1B Biomarker Blood Test for early lung cancer detection, was brought to the forefront during this significant gathering. This test aims to provide physicians with critical biomarker information to enhance clinical decision-making, complementing existing diagnostic techniques. With aspirations set on a phased national rollout, the test is currently available to licensed healthcare providers in Texas areas including Dallas-Fort Worth and San Antonio.

As Cizzle Bio continues to make strides in innovative cancer diagnostics, the company's commitment to partnering with initiatives like the Prevent Cancer Foundation remains steadfast. Their work to unify research, advocacy, and patient voice around early detection is crucial and impactful. "We are proud to support Prevent Cancer and its mission to strengthen cancer prevention efforts, ultimately uniting research, education, advocacy, and the patient voice," Behnke reiterated.

Cizzle Bio's commitment to revolutionizing cancer diagnostics illustrates the importance of innovation in healthcare. Their dedication is not just about advancing technology but also about touching lives—one biomarker test at a time. For more information about Cizzle Bio and their groundbreaking initiatives in cancer diagnostics, explore CizzleBio.com.